Dune Medical Devices of Framingham has passed another federal approval phase for a breast-cancer surgical tool, MarginProbe, the company announced today.
Dune received a go-ahead from the U.S. Food and Drug Administration on its pre-market approval application, subject to final agreement with the agency on the design of a required post-approval study.
MarginProbe uses radio frequency spectroscopy to characterize breast tissue during surgery to determine if any tumor margins are malignant.
